BIRC5 and prostate cancer: Overexpression of survivin has been implicated in ovarian cancer [68,69], colorectal cancer [70], breast cancer [71], prostate cancer [72], gastrointestinal cancer [73], lymphoma [74,75], acute myeloid leukemia (AML) [76,77], and chronic myeloid leukemia (CML) [78,79].